Search
Mibefradil
go.drugbank.com/drugs/DB01388ApprovedWithdrawnMibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.
Serelaxin
go.drugbank.com/drugs/DB05794Investigationalbones come together).It is a heterodimer protein secreted by the corpus luteum and placenta during pregnancy. … Recombinant human relaxin is a hormone produced during pregnancy that facilitates the birth process by causing a softening and lengthening of the cervix and the pubic symphysis (the place where the pubic
Saredutant
go.drugbank.com/drugs/DB06660InvestigationalSaredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.
AAV-AIPL
go.drugbank.com/drugs/DB17857ExperimentalDeveloped by MeiraGTx, it is being investigated for the treatment of inherited retinal dystrophy due to defects in _AIPL1_ gene.
Amitriptylinoxide
go.drugbank.com/drugs/DB13114ApprovedWithdrawnAmitriptylinoxide has been used in trials studying Major Depression.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeRheinanthrone
go.drugbank.com/drugs/DB13175ExperimentalIt is commonly produced by plants of the Rheum species [L772].
TM30339
go.drugbank.com/drugs/DB05085ExperimentalTM30339 works through the same receptor as the natural satiety hormone, Pancreatic Polypeptide (PP), but TM30339 has improved properties compared with PP.
Poractant alfa
go.drugbank.com/drugs/DB09113ApprovedInvestigationalIt is used to treat Respiratory Distress Syndrome (RDS) in premature infants with an endogenous pulmonary surfactant deficiency. … It contains no preservatives.
Fucoxanthin
go.drugbank.com/drugs/DB15462Investigational, but the exact mechanism of anti-cancer action of fucoxanthin is not fully elucidated. … Fucoxanthin causes antitumor and anticarcinogenic effects by inducing G1 cell-cycle arrest and apoptosis by modulating expression of various cellular molecules and cellular signal transduction pathways
AAV1-FS344
go.drugbank.com/drugs/DB17855InvestigationalAAV1-FS344 is an investigational gene therapy developed by Milo Biotechnology to deliver follistatin, a potent myostatin inhibitor.